CHM-0201

N/A

Report date: 2022/12/18 18:44:36

Base Information

Drug NameCHM-0201
Drug Alias NameCHM-0201CHM0201CHM 0201 (CORE-NK Platform)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChimeric Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesChimeric Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A